Ken Griffin
BIOSU

Ken Griffin’s BioPlus Acquisition Corp. Unit BIOSU Stock Holding History

Ken Griffin’s Portfolio BIOSU Stock Details BIOSU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-750,000
Closed -$7.5M – 14944
2021
Q4 		$7.5M Buy
+750,000
New +$7.51M ﹤0.01% 3578

Other funds holding BIOSU

Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.76% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ken Griffin's BIOSU Position: Q1 2022 in Review

Ken Griffin sold out of BioPlus Acquisition Corp. Unit (BIOSU) in Q1 2022, closing a stake of 750,000 shares — an estimated $7.5M sold.

Ken Griffin first reported a position in BIOSU in Q4 2021 and held it in 1 quarter. The position peaked at $7.5M in Q4 2021. 30 funds tracked by Wall St. Rank hold BIOSU as of Q1 2022.

  • Ken Griffin reported no remaining BioPlus Acquisition Corp. Unit position as of Q1 2022 after selling out during the quarter.
  • Ken Griffin sold 750,000 BioPlus Acquisition Corp. Unit shares in Q1 2022, an estimated $7.5M.
  • Ken Griffin first reported a position in BioPlus Acquisition Corp. Unit in Q4 2021 and held it in 1 quarter.
  • Ken Griffin's BioPlus Acquisition Corp. Unit position peaked at $7.5M in Q4 2021.
  • 30 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Unit as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.